Clinical Trial Update: A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity of dasiglucagon and GlucaGen in people with Type 1 diabetes; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoglycemia
• Type 1 Diabetes Mellitus

Drugs mentioned

• GlucaGen (glucagon)
• dasiglucagon (dasiglucagon)

Snippet

Sponsor: Zealand Pharma | Conditions: Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2021-02-16